{
  "docId": "019de074-f95f-763f-9a80-be3b653e0df1",
  "docSlug": "502ed4e7545b260f09647399e486ae2c",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 28 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 28,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a timeline-based process diagram to illustrate the clinical trial structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-f95f-763f-9a80-be3b653e0df1/16",
  "deckHref": "/decks/019de074-f95f-763f-9a80-be3b653e0df1",
  "deckJsonHref": "/decks/019de074-f95f-763f-9a80-be3b653e0df1.json",
  "deckAnchorHref": "/decks/019de074-f95f-763f-9a80-be3b653e0df1#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.21,
        "x": 0.51,
        "y": 0.78
      },
      "kind": "callout",
      "text": "PRIMARY ENDPOINT: All-cause mortality at 42 days",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc677902-eaac-4b72-ab5d-02947e17a806",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.92,
        "x": 0.04,
        "y": 0.31
      },
      "kind": "diagram",
      "text": "Clinical trial design timeline showing initial treatment vs step-down treatment phases.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bf04720-c874-4c48-9c11-372c4caffd7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.04,
        "y": 0.78
      },
      "kind": "list",
      "text": "IFIs in patients with LIMITED TREATMENT OPTIONS: Invasive candidiasis, candida cystitis, endemic mycoses, etc.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d5b6e94-d673-49dd-a78c-4a2daf104849",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.74,
        "y": 0.78
      },
      "kind": "list",
      "text": "SECONDARY ENDPOINTS: Overall response, All-cause mortality at 84 days, Safety and tolerability, Pharmacoeconomic impact",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b967d73-e395-4918-8149-1d26d668f60a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "To assess the efficacy, safety, and tolerability of MAT2203 in patients with Invasive Aspergillosis; Patients will be randomized 2:1 to receive either oral MAT2203 as “step down” treatment after initial treatment with IV AMB (Experimental Arm) or Standard of Care (Comparator Arm)\nNon-randomized experimental arm: patients with serious, life-threatening IFIs with limited treatment options will receive oral MAT2203 as “step down” treatment after initial treatment with IV AMB (or an echinocandin)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30c517d1-161f-47bd-b7ea-51bc0397f920",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "*Numbers based on 20% NI margin and 85% power",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d8a3555-6f08-4a6a-aaa1-3d58a02261e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase III Aspergillus/IFI Study – Preliminary Design (Subject to FDA Agreement)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c9691e1-8a49-48d2-9094-8992c5f2f6b1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Hypothesis-Driven Structure",
      "slug": "hypothesis-driven-structure",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "01eb00fe-c7e0-4035-b7b0-d4da4285f685",
      "evidence": "PRIMARY ENDPOINT: All-cause mortality at 42 days",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "3c7ce2f4-a5c2-4431-967f-850408b80f55",
      "evidence": "The diagram uses a timeline-based structure to show treatment phases across patient arms.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}